Today: 11 June 2026
Salesforce stock today: CRM barely budges as year-end tech trade cools — what investors watch next
30 December 2025
1 min read

Salesforce stock today: CRM barely budges as year-end tech trade cools — what investors watch next

NEW YORK, December 29, 2025, 18:19 ET — After-hours

Salesforce, Inc. shares edged higher on Monday and were flat in after-hours trading, holding up better than the broader tech sector as Wall Street entered the final three sessions of 2025. The stock ended up 0.06% at $266.23 and was little changed after 4 p.m. ET, when shares continue to trade outside regular market hours.

The muted move matters now because investors are testing how much of 2025’s technology-led rally can carry into January, with year-end positioning keeping trading choppy.

Salesforce is also a bellwether for enterprise software budgets, and its push to sell “AI agents” — software that can take actions across customer-service and sales workflows — keeps it linked to the market’s AI trade.

U.S. stocks finished lower on Monday as heavyweight technology names retreated from last week’s rally: the Nasdaq fell 118.75 points, or 0.50%, while the S&P 500 slipped 0.35%, a Reuters report said. “This is not the beginning of the end of the tech dominance — it’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust. Investors are watching minutes from the Federal Reserve’s last meeting and weekly jobless claims later this week; some have been looking for a “Santa Claus rally,” the seasonal tendency for stocks to rise at year-end. Reuters

Other enterprise-software names were mixed in late trading, with ServiceNow up about 0.5% and Oracle down about 1.3%. Microsoft slipped about 0.1%.

Salesforce raised its annual outlook earlier this month, leaning on demand for its AI agent platform. It guided to fiscal 2026 revenue of $41.45 billion to $41.55 billion and adjusted earnings per share of $11.75 to $11.77, Reuters reported on Dec. 3.

Salesforce sells cloud-based customer relationship management software, which businesses use to track and manage sales, customer service and marketing. Its Agentforce platform lets companies build and deploy AI agents that can respond to inputs and take actions across business functions, according to a Reuters company profile.

With the stock near $266, investors are looking for evidence that new AI features translate into larger contract volumes without pressuring pricing on existing products.

Any sign that corporate software spending is slowing tends to hit large subscription vendors quickly, even on days with no Salesforce-specific headlines.

Salesforce has not announced the date for its next quarterly report. Data provider estimates compiled by MarketBeat point to late February, with Feb. 25, 2026 flagged as a tentative slot.

The next update will put focus on booking trends and sales pipeline — forward-looking gauges for subscription growth — and on whether AI-driven deals are recurring revenue rather than one-time projects.

In the near term, traders will watch whether shares can push through the $270 area or drift back toward $260, with broader tech sentiment likely to do most of the driving.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake
Next Story

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake

Go toTop